UIH(SH:688271)2023-04-27 16:00Financial Performance - The company's revenue for Q1 2023 reached ¥2,212,870,463.39, representing a year-on-year increase of 33.42%[4] - Net profit attributable to shareholders was ¥329,659,181.62, reflecting a growth of 7.68% compared to the same period last year[4] - Operating profit for Q1 2023 was RMB 363,206,481.37, slightly up from RMB 360,574,427.16 in Q1 2022[17] - Net profit for Q1 2023 was RMB 325,526,611.76, compared to RMB 301,681,648.10 in Q1 2022, reflecting an increase of 7.9%[17] - Comprehensive income for Q1 2023 totaled RMB 320,718,943.78, compared to RMB 296,414,888.38 in Q1 2022, an increase of 8.2%[18] Research and Development - R&D investment totaled ¥430,404,096.92, which is 19.45% of the revenue, an increase of 4.05 percentage points year-on-year[4] - Research and development expenses for Q1 2023 amounted to RMB 412,457,903.29, up from RMB 225,313,935.37 in Q1 2022, indicating a significant investment in innovation[17] Cash Flow and Management - The net cash flow from operating activities was negative at -¥313,565,330.56, indicating a significant change in cash management[4] - Cash flow from operating activities in Q1 2023 was RMB 2,400,333,807.83, compared to RMB 1,358,475,956.46 in Q1 2022, showing a strong increase of 76.7%[19] - The company reported a net increase in cash and cash equivalents of -1,799,155,142.95, compared to -1,939,336,075.03 in the previous year[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥24,233,214,669.96, showing a slight increase of 0.12% from the end of the previous year[5] - The company's current assets totaled RMB 20,167,991,458.87, compared to RMB 20,144,563,385.67 in the previous period, indicating a marginal increase of about 0.12%[13] - The total liabilities decreased to RMB 6,425,306,357.89 from RMB 6,731,009,468.77, representing a reduction of approximately 4.54%[15] - The company's equity attributable to shareholders increased to RMB 17,817,607,290.73 from RMB 17,483,275,310.26, reflecting a growth of approximately 1.91%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,877[8] - The top shareholder, 联影医疗技术集团, holds 20.33% of the shares, amounting to 167,550,968 shares[9] Government Subsidies - The company received government subsidies amounting to ¥41,348,453.47, which are closely related to its normal business operations[6] Operating Costs - Total operating costs for Q1 2023 were RMB 1,949,098,408.01, up from RMB 1,387,605,701.78 in Q1 2022, representing an increase of 40.5%[16] Tax and Other Income - The company’s tax expenses for Q1 2023 were RMB 34,014,094.44, down from RMB 53,418,742.19 in Q1 2022, reflecting a decrease of 36.4%[17] - Other income for Q1 2023 was RMB 108,082,436.09, compared to RMB 129,075,139.81 in Q1 2022, indicating a decrease of 16.3%[17]